Dr Luke Marinovich (PhD, MPH, BA(Hons)) is a mid-career researcher with a background in the evaluation of new health technologies, particularly tests for breast cancer screening, staging and treatment monitoring. His research on tomosynthesis for breast cancer screening and MRI for monitoring neoadjuvant therapy has informed international practice guidelines and policy decisions about adoption of those technologies. Through two consecutive postdoctoral fellowships, he contributed to the development of evidence-based international consensus guidelines for the surgical management of early invasive and non-invasive breast cancer, and demonstrated their translational impact in reducing unnecessary reoperations. Currently, Dr Marinovich leads a National Breast Cancer Foundation-funded research program on artificial intelligence (AI) for improving breast cancer screening, including evaluation of AI’s comparative accuracy, cost effectiveness, and acceptability to the community. He has over 50 peer-reviewed publications, in addition to 20 health technology assessment reports to the Australian Government.
